Arkolith/Insider Trading/JANX/Form 4

Meyer Andrew Hollman

Chief Business OfficerJanux Therapeutics, Inc. (JANX) · full profile →Form 4 · filed Oct 30, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$501K
Net Open-Market Flow
-$501K
Transactions
5
3 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Oct 28, 2025Sell(S)17K$30.06$501K82K
Oct 28, 2025Option exercise(M)10K$4.21$42K92K
Oct 28, 2025Option exercise(M)7K$10.59$71K99K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Oct 28, 2025Option exercise(M)7K—$0121K
Oct 28, 2025Option exercise(M)10K—$077K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001864159-25-000003) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML